<DOC>
	<DOC>NCT00497471</DOC>
	<brief_summary>The purpose of this trial is to evaluate the efficacy of weekly iron supplementation and the efficacy of malaria chemoprophylaxis from 2 to 12 months of age in infants living in an area of intense and perennial malaria transmission</brief_summary>
	<brief_title>RCT Iron Supplementation and Malaria Chemoprophylaxis for Prevention of Severe Anemia and Malaria in Tanzanian Infants</brief_title>
	<detailed_description>411 Tanzanian infants were randomly assigned to receive weekly malaria prophylaxis with Deltaprimâ„¢ (3.125 mg pyrimethamine plus 25 mg dapsone) or placebo from ages 2-12 months. Children were followed-up until age 4 years. Uncomplicated febrile malaria, severe malaria and anaemia morbidity were assessed through hospital-based passive surveillance.</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Iron</mesh_term>
	<mesh_term>Dapsone</mesh_term>
	<mesh_term>Pyrimethamine</mesh_term>
	<criteria>Born in San Francis Designated District Hospital of Ifakara Obvious severe congenital malformation such as: spina bifida, hydrocephalus or anencepahlus Twins Birth weight &lt; 1,5 kg Clinical signs of cerebral asphyxia Clinical signs of neonatal or congenital infection Mother unreliable (deaf, mentally handicapped)</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>1 Day</maximum_age>
	<verification_date>July 2007</verification_date>
	<keyword>Plasmodium Falciparum</keyword>
	<keyword>Antimlarial chemoprophylaxis</keyword>
	<keyword>Iron supplementation</keyword>
	<keyword>Tanzania</keyword>
</DOC>